Abbvie (ABBV) has been active on multiples fronts in the biotech space. The company has recently achieved significant milestones for its products in several therapeutic markets, garnering attention from industry analysts.
CHMP approved the extended use of its lymphoma drug and its novel therapy
Skyrizi received FDA approval for
Ulcerative Colitis, strengthening its IBD portfolio. The FDA expansions of
Epkinly and
risankizumab-rzaa labels will further solidify the company's market position. In addition to product development, Abbvie has sealed major deals including the license agreement with FutureGen, collaboration with Gilgamesh Pharmaceuticals, and acquisitions of Landos Biopharma and Celsius Therapeutics. On the downside it encountered regulatory hurdles as its Parkinson's drug was rejected by the
FDA twice in quick succession. In terms if the investment sentiment, certain investors seem optimistic with notable shares purchase activities, but the generally mixed forecasts and hiccups in its Parkinson's Disease portfolio have led to some stock price volatility. Finally, the company experienced a leadership transition with Robert A. Michael being appointed as their new CEO.
Abbvie ABBV News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 07 Jul 2024 14:59:21 GMT -
Rating 3
- Innovation 5
- Information 8
- Rumor -5
